StemInov

StemInov is a French clinical-stage biotechnology company focused on developing allogeneic cell therapies for inflammatory and life-threatening conditions. The company utilizes a proprietary process to isolate and expand Mesenchymal Stem Cells (MSCs) from the Wharton's Jelly of the umbilical cord. Its lead therapeutic candidate, STE-01, is designed to treat patients with septic shock and Acute Respiratory Distress Syndrome (ARDS) by modulating the host's immune response and reducing systemic inflammation. StemInov operates as a spin-off from the University of Lorraine and the Nancy University Hospital, benefiting from strong academic and clinical ties. The company's mission is to provide standardized, off-the-shelf regenerative medicine products for intensive care medicine.